Dacarbazine

CAS No.

4342-03-4

MDL No.

MFCD00057167

C₆H₁₀N₆O

182.18

InChI Key

FDKXTQMXEQVLRF-ZHACJKMWSA-N

Pack Size	Purity	Price	Availability
250 mg	98%	$12	In Stock
1 g	98%	$25	In Stock
5 g	98%	$97	In Stock
10 g	98%	$177	In Stock
25 g	98%	$351	In Stock
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

250 mg

98%

$12

In Stock

1 g

98%

$25

In Stock

5 g

98%

$97

In Stock

10 g

98%

$177

In Stock

25 g

98%

$351

In Stock

Custom synthesis and bulk supply options are available upon request.

Product Information

Dacarbazine can cause cancer, as determined by an independent committee of scientific and health experts. It may also cause developmental toxicity, as indicated by state or federal government labeling requirements.

CAS No.	4342-03-4
Product Name	Dacarbazine

Associated Conditions

lymphoma·skin cancer·leiomyosarcoma·soft tissue sarcoma·neuroendocrine neoplasm·

* The information provided here is compiled from public sources and is for reference only.

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Documentation

Dacarbazine

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Associated Conditions

Related Articles

Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.

Dacarbazine-induced carotid artery and deep venous thrombosis in a patient with leiomyosarcoma: case report.

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.

Documentation

Similar Products

Dacarbazine citrate